Radiology:乳腺癌的二维数字乳腺X线成像(DM)与数字乳腺断层融合术(DBT)筛查及间隔期癌的相关性研究

2018-02-27 shaosai MedSci原创

目的:确定二维数字乳腺X线成像(DM)与数字乳腺断层融合术(DBT)在筛查率和间隔期癌肿瘤特征中是否存在差异。

目的:确定二维数字乳腺X线成像(DM)与数字乳腺断层融合术(DBT)在筛查率和间隔期癌肿瘤特征中是否存在差异。

材料及方法:回顾了2009年1月至2011年2月(DM组,DBT整合前)和2013年1月至2015年2月(DBT组,完整DBT整合后)连续筛查乳腺X线片。如果在筛查后365天内诊断阳性结果则是癌症;365天内诊断为阴性结果则为间隔期癌。使用Z检验比较DM和DBT两种检查手段。

结果:在78 385 DM检查和76 896 DBT检查中,共诊断出948例乳腺癌。虽然DM和DBT 总体的筛查率一样(5.0 vs 5.0 每 1000 例检查, P = .98),DBT检查中较高比例的癌症是侵袭性,而不是原位癌(74.2% [287/387] vs 66.0% [260/394], P = .01)。DM与DBT的筛查中,在病理检查中肿瘤的大小、分级、激素受体状态、淋巴结状态等肿瘤特征上,无显着性差异(P = .09-.99)。DM与DBT的筛查中,间隔期肿瘤的的检查率是一样的(1.1 vs 1.1 每 1000 例检查, P = .84)。与症状性间隔癌症相比,磁共振成像检测的间隔癌症更可能是微小癌。

结论:筛查及间隔癌的检出中DM与DBT两种检查方式相似,但是DBT筛查中的癌症较高比例是侵袭性癌而不是原位癌。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-04 大爰

    学习并分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-01 piaojinhua
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-01 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837463, encodeId=be57183e4630e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Nov 08 16:11:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292837, encodeId=0b9729283e4a, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 04 08:21:24 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298013, encodeId=4edf1298013b5, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525465, encodeId=e894152546522, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546193, encodeId=f0631546193c1, content=<a href='/topic/show?id=807a8886416' target=_blank style='color:#2F92EE;'>#融合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88864, encryptionId=807a8886416, topicName=融合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594299, encodeId=a07115942994e, content=<a href='/topic/show?id=ebb35e364c' target=_blank style='color:#2F92EE;'>#DBT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5736, encryptionId=ebb35e364c, topicName=DBT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Mar 01 12:11:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-01 智智灵药

相关资讯

CLIN CANCER RES:乳腺癌生存新的预后指标

乳腺癌是肿瘤相关死亡的主要原因,需要发现理想的预后标志以改善患者结局。CLIN CANCER RES近期发表了一篇文章,研究miRNA相关基因和乳腺癌生存之间的关系。

Lancet Oncol:早期乳腺癌新辅助化疗真的值得疯狂打call吗?

新辅助化疗(NACT)出现初期,常用于难以手术治疗的局部进展期乳腺癌和炎性乳腺癌,以期缩小病变,为手术治疗创造机会。如今,NACT用于增加乳腺癌患者接受保乳治疗的机会和根除微小转移病灶。然,任何事情都有两面性,NACT真的值得我们疯狂打call吗?

Lancet oncol:芳香化酶抑制剂治疗乳腺癌的更佳时间,以及三种芳香化酶抑制剂的疗效对比

目前,利用芳香化酶抑制剂辅助治疗乳腺癌的最佳时间尚不确定,现也无临床试验直接对比三种芳香化酶抑制剂阿那曲唑(anastrozole)、依西美坦(exemestane)和来曲唑( letrozole)的效果。近日,Lancet子刊上发表一篇文章,研究人员对芳香化酶抑制剂用作辅助治疗雌激素受体阳性的早期乳腺癌的时间和类型进行评估。研究人员进行多中心的、开放性、随机化临床三期试验(FATA-GIM3),

NCCN临床实践指南:乳腺癌(2017.V4)

2018年2月,美国国家综合癌症网络(NCCN)发布了乳腺癌管理指南2017年第4版,指南主要内容涉及: 指南更新摘要 非浸润性乳腺癌 浸润性乳腺癌 特殊考虑

CLIN CANCER RES:循环肿瘤DNA和循环肿瘤细胞:晚期乳腺癌综合液体活检分析

液体活检可以对转移性乳腺癌进行实时的评估。CLIN CANCER RES近期发表了一篇文章,评估联合循环肿瘤细胞(CTC)循环肿瘤DNA(ctDNA)预测转移性乳腺癌预后的效果。

Radiology:立体定位真空辅助活检发现乳腺高危病变怎么办?

本研究为了评价在立体定位活检检出高危病变诊断后且有或无手术切除进行每年一次或两年一次钼靶检查的依从性并验证影响筛查依从性的临床因素,研究人员将结果发表在Radiology上。